Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

Core Viewpoint - Gyre Therapeutics has received priority review status from China's NMPA for its New Drug Application for Hydronidone (F351), aimed at treating chronic hepatitis B-induced liver fibrosis, marking a significant milestone in the drug approval process [1][2]. Group 1: Company Overview - Gyre Therapeutics is a biopharmaceutical company based in San Diego, focused on developing and commercializing innovative treatments for liver fibrosis, including Hydronidone [8]. - Gyre Pharmaceuticals, a majority-owned subsidiary of Gyre Therapeutics, has a pipeline that includes Hydronidone, which has shown statistically significant fibrosis regression in clinical trials [7]. Group 2: Drug Information - Hydronidone (F351) is an orally administered anti-fibrotic agent that targets liver fibrosis pathways by inhibiting TGF-β1-induced signaling, which is crucial for fibrogenesis [4]. - The drug has completed Phase 3 clinical evaluation in China for chronic hepatitis B-associated liver fibrosis, including cases of early compensated cirrhosis [5]. Group 3: Market Context - Chronic hepatitis B (CHB) infection affects approximately 254 million people globally, with a significant number developing liver fibrosis and cirrhosis, highlighting the urgent medical need for effective treatments like Hydronidone [6]. - The prevalence of CHB is particularly high in China and the United States, making the potential market for Hydronidone substantial [6]. Group 4: Regulatory Insights - The priority review designation by the NMPA was established to expedite the drug registration process for innovative therapies, allowing for faster evaluation and resource allocation [3].